title: Increasing feasibility and utility of (18)F-FDOPA PET for the management of glioma.
abstract: BACKGROUND
  Despite radical treatment therapies, glioma continues to carry with it a uniformly poor prognosis. Patients diagnosed with WHO Grade IV glioma (glioblastomas; GBM) generally succumb within two years, even those with WHO Grade III anaplastic gliomas and WHO Grade II gliomas carry prognoses of 2-5 and 2 years, respectively. PET imaging with (18)F-FDOPA allows in vivo assessment of the metabolism of glioma relative to surrounding tissues. The high sensitivity of (18)F-DOPA imaging grants utility for a number of clinical applications.
  
  
  METHODS
  A collection of published work about (18)F-FDOPA PET was made and a critical review was discussed and written.
  
  
  RESULTS
  A number of research papers have been published demonstrating that in conjunction with MRI, (18)F-FDOPA PET provides greater sensitivity and specificity than these modalities in detection, grading, prognosis and validation of treatment success in both primary and recurrent gliomas. In further comparisons with (11)C-MET, (18)F-FLT, (18)F-FET and MRI, (18)F-FDOPA has shown similar or better efficacy. Recently synthesis cassettes have become available, making (18)F-FDOPA more accessible.
  
  
  CONCLUSIONS
  According to the available data, (18)F-FDOPA PET is a viable radiotracer for imaging and treatment planning of gliomas.
  
  
  CONCLUSIONS
  (18)F-FDOPA PET appears to be a viable radiopharmaceutical for the diagnosis and treatment planning of gliomas cases, improving on that of MRI and (18)F-FDG PET.
authors.affiliation: CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia; The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia.
authors.forename: Christopher
authors.initials: C
authors.lastname: Bell
authors.affiliation: CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Dowson
authors.affiliation: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St. Lucia QLD 4072, Australia.
authors.forename: Simon
authors.initials: S
authors.lastname: Puttick
authors.affiliation: The University of Queensland, Centre for Medical Diagnostic Technologies in Queensland, St. Lucia QLD 4072, Australia.
authors.forename: Yaniv
authors.initials: Y
authors.lastname: Gal
authors.affiliation: Department of Radiation Oncology, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia.
authors.forename: Paul
authors.initials: P
authors.lastname: Thomas
authors.affiliation: The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia; Genesis Cancer Care, Lake Macquarie Private Hospital, 36 Pacific Highway, Gateshead NSW 2290, Australia; Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia.
authors.forename: Mike
authors.initials: M
authors.lastname: Fay
authors.affiliation: The University of Queensland, School of Medicine, St. Lucia QLD 4072, Australia; Specialised PET Services Queensland, Royal Brisbane and Women's Hospital, Herston QLD 4029, Australia.
authors.forename: Jye
authors.initials: J
authors.lastname: Smith
authors.affiliation: CSIRO Preventative Health Flagship, CSIRO Computational Informatics, The Australian e-Health Research Centre, Herston QLD 4029, Australia. Electronic address: Stephen.Rose@csiro.au.
authors.forename: Stephen
authors.initials: S
authors.lastname: Rose
mesh_terms: D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D005240:Feasibility Studies; D005910:Glioma / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D060787:Neoplasm Grading; D049268:Positron-Emission Tomography / Q000379:methods*; D011880:Radiotherapy Planning, Computer-Assisted
chemical_list: C043437:fluorodopa F 18; D004295:Dihydroxyphenylalanine
keywords: (18)F-FDOPA; Dopamine; Glioblastoma; Glioma; Infiltration; PET